Effects of Blood Pressure Reduction on High Sensitivity C-Reactive Protein (hsCRP).

Trial Profile

Effects of Blood Pressure Reduction on High Sensitivity C-Reactive Protein (hsCRP).

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Nov 2011

At a glance

  • Drugs Hydrochlorothiazide; Valsartan
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Nov 2011 Actual patient number is 1677 according to ClinicalTrials.gov.
    • 07 Nov 2011 Actual end date (June 2005) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top